Corbus Pharmaceuticals (NASDAQ:CRBP) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.04), Bloomberg Earnings reports. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 85.97%.
Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) opened at $6.75 on Wednesday. Corbus Pharmaceuticals has a 12 month low of $5.30 and a 12 month high of $10.50. The company has a market capitalization of $391.37, a PE ratio of -10.38 and a beta of 2.09.
CRBP has been the topic of several research analyst reports. Raymond James Financial initiated coverage on Corbus Pharmaceuticals in a research note on Friday, January 19th. They issued an “outperform” rating and a $24.00 price objective on the stock. BidaskClub lowered Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals in a research note on Friday, December 29th. Cantor Fitzgerald set a $28.00 price objective on Corbus Pharmaceuticals and gave the company an “overweight” rating in a research note on Thursday, December 14th. Finally, ValuEngine raised Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Corbus Pharmaceuticals has an average rating of “Buy” and a consensus price target of $25.75.
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.